Which albuterol method works best for rare lung disease?
NCT ID NCT01799538
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This study tests whether a nebulizer or a standard inhaler delivers albuterol better to improve breathing in women with LAM, a rare lung disease. About 100 women with reduced lung function will stay overnight for 3 days to try each method. The goal is to see which approach opens the airways more effectively.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHANGIOLEIOMYOMATOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massive TSC data and tissue bank opens to researchers
- Blood markers may guide LAM treatment dosing
- New PET scan could reveal early drug response in rare lung disease
- Could a leukemia drug help treat rare lung disease LAM? new trial launches
- New registry tracks pregnancy risks in rare genetic disorders
- Scientists dive deep into the roots of a mysterious lung disease